The OSTIAL Study (Optimization of Stent Placement in Aorto-ostial Lesions) (OSTIAL)

September 22, 2026 updated by: Centre Cardiologique du Nord

Optimisation du Positionnement Des Stents Dans Les lésions Aorto-ostiales : étude Multicentrique Historico-prospective Avec Phase randomisée Comparant l'Angioplastie Coronaire Avec ou Sans Technique du Floating Ballon Étude OSTIAL (Optimizing Stent In Aorto-Ostial Lesion)

Aorto-ostial coronary lesions present a significant challenge during coronary angioplasty. This is due to the difficulty of precisely identifying the aorto-ostial plane and the frequent instability of the guiding catheter during stent deployment.

Despite the angiographic appearance being deemed optimal, several studies have shown a high rate of suboptimal stent positioning at the ostium when subsequent coronary CT angiography (CCTA) assessment is performed.

This suboptimal positioning may be linked to incomplete ostial coverage, which could increase the risk of in-stent restenosis. It may also be linked to excessive stent protrusion into the aorta, which could compromise future procedures, particularly in the context of transcatheter aortic valve replacement.

The "Floating Balloon" (FB) technique has been developed to improve system stability and to reliably mark the aorto-ostial landing zone (AOLZ). A previous study demonstrated the feasibility and accuracy of this technique.

The aim of the current study is to assess the clinical effectiveness of the Floating Balloon. Although this technique is already in use, no study has yet conducted a systematic assessment of stent positioning using CCTA.

The study utilised a combined retrospective-prospective approach to comprehensively evaluate the incidence of suboptimal stent positioning associated with the Floating Balloon technique. This evaluation was conducted by systematically comparing patient outcomes between those treated with the FB and those treated without the FB. The study employed CCTA as a key tool to assess stent position, ensuring a precise analysis of the data.

To achieve this, it is recommended that follow-up data from patients who have already undergone the FB procedure and had their stent position assessed via CCTA (retrospective component) be analysed, while also enrolling new patients and randomizing them into FB and non-FB groups (prospective component).

Study Overview

Detailed Description

In order to address the primary objective (namely, to estimate the rate of stent malpositioning), 97 evaluable subjects are required to achieve a precision (half-width of the 95% confidence interval) of +/-10% (assuming a conservative 50% rate of correct positioning).

As assessments are conducted immediately after the procedure, the investigators do not anticipate a significant number of non-evaluable subjects. The proposal is to enrol N=100 subjects in the FB group, with 50 subjects in the retrospective phase and another 50 in the prospective phase.

In order to address the secondary objective of comparing malpositioning rates between the two groups (with and without FB), patients in the non-FB group should be enrolled at a 1:2 ratio. The justification for this number is based on feasibility. This will provide preliminary data for the non-FB group.

Therefore, given our retrospective cohort of 50 FB subjects with available measurements, the prospective phase will include N=50 + 25-or 75 additional subjects (50 in the FB arm and 25 in the non-FB arm). The analyses will therefore cover a total of 125 subjects (100 with FB and 25 without FB).

Study Type

Interventional

Enrollment (Estimated)

75

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Frank FD DIGNE, PHD
  • Phone Number: 01 49 33 41 13
  • Email: f.digne@ccn.fr

Study Contact Backup

Study Locations

      • Bois-Bernard, France
      • Clermont-Ferrand, France
      • Creil, France
      • Massy, France
        • Institut Cardiovasculaire Paris Sud - Massy
        • Contact:
      • Saint-Denis, France
        • Centre cardiologique du nord
        • Contact:
          • Frank FD DIGNE, PHD
          • Phone Number: 01 49 33 41 13
          • Email: f.digne@ccn.fr
        • Contact:
          • Karima KM MOUSSOUNI, Cra
          • Phone Number: 0679145144
        • Sub-Investigator:
          • Arthur AD DARMON, Dr
      • Saint-Etienne, France

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female aged over 18 years
  • Prospective part: Patient who has signed an informed consent form
  • Retrospective part: No objection to the use of personal data for this research
  • Indication for coronary angioplasty for an aorto-ostial lesion (right coronary artery or left main coronary artery) for patients included in the prospective part / Patients in the historical part who underwent coronary angioplasty for an aorto-ostial lesion (right coronary artery or left main coronary artery) using the "floating balloon" (FB) technique, followed by a CCTA assessment of positioning
  • Affiliation with or beneficiary of a social security scheme.

Exclusion Criteria:

  • Contraindication to coronary CT angiography (severe renal impairment not requiring dialysis (GFR ≤ 30 ml/min)), applicable only to patients included in the prospective part
  • Refusal of consent (patients included in the prospective part)
  • Objection to the use of personal data (patients in the retrospective part)
  • Patient unable to read, write, or understand French
  • Vulnerable patient as defined by Article L1121-6 of the Public Health Code (CSP)
  • Adult patient placed under guardianship, curatorship, or judicial protection
  • Patient unable to personally provide consent pursuant to Article L.1121-8 of the CSP, or an adult under legal protection
  • Pregnant or breastfeeding woman as defined by Article L1121-5 of the CSP

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Coronary angioplasty using the floating balloon technique

Coronary angioplasty using the FB technique involves the following steps:

  1. Crossing the aorto-ostial lesion using a standard coronary guidewire positioned in the target artery.
  2. Withdrawing the guiding catheter from the ostium and placing a second guidewire, formed into a loop, within the aortic root.
  3. Inflating a small-diameter (2 mm) balloon in the aorta over the second guidewire; this serves as the "floating balloon."
  4. Advancing the stent toward the target lesion.
  5. Gradually withdrawing the floating balloon until its proximal marker contacts the tip of the guiding catheter, thereby defining the aorto-ostial plane and the aorto-ostial landing zone (AOLZ).
  6. Maintaining forward pressure on the guiding catheter to stabilize the entire system and limit selective engagement of the ostium.
  7. Aligning the stent's proximal marker with the balloon marker and the tip of the guiding catheter, followed by gradual deployment of the stent.
Active Comparator: Coronary angioplasty without the floating-balloon technique

Angioplasty of the aorto-ostial lesion without the jailed-balloon (FB) technique will be performed as follows:

  1. Coronary catheterization via the access route chosen by the operator
  2. Predilatation, if deemed necessary
  3. Implantation of a drug-eluting stent (DES) sized according to angiographic or QCA assessment
  4. Final optimization (post-dilatation, POT, or other techniques) at the operator's discretion

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The number of participants in whom stent placement was technically successful and who were evaluated by CT scan.
Time Frame: At the end of the procedure
At the end of the procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The secondary outcome is the rate of major adverse cardiovascular events (MACE).
Time Frame: 12 months after the surgery procedure

The secondary outcome is the rate of major adverse cardiovascular events (MACE), including cardiac mortality, all-cause mortality, myocardial infarction (MI), target lesion revascularization (TLR) and hospitalisation for cardiovascular causes.

12 months after the surgery procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Frank FD DIGNE, PHD, Centre Cardiologique du Nord

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 30, 2026

Primary Completion (Estimated)

October 30, 2028

Study Completion (Estimated)

October 30, 2028

Study Registration Dates

First Submitted

September 14, 2026

First Submitted That Met QC Criteria

September 18, 2026

First Posted (Actual)

September 22, 2026

Study Record Updates

Last Update Posted (Actual)

September 24, 2026

Last Update Submitted That Met QC Criteria

September 22, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe